Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATRC 
AtriCure Inc (ATRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ATRC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $50
1 Year Target Price $50
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.01% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.74B USD | Price to earnings Ratio - | 1Y Target Price 50 |
Price to earnings Ratio - | 1Y Target Price 50 | ||
Volume (30-day avg) 9 | Beta 1.62 | 52 Weeks Range 25.57 - 43.11 | Updated Date 09/14/2025 |
52 Weeks Range 25.57 - 43.11 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.27% | Operating Margin (TTM) -4.55% |
Management Effectiveness
Return on Assets (TTM) -3.53% | Return on Equity (TTM) -7.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1702483624 | Price to Sales(TTM) 3.49 |
Enterprise Value 1702483624 | Price to Sales(TTM) 3.49 | ||
Enterprise Value to Revenue 3.41 | Enterprise Value to EBITDA -135.97 | Shares Outstanding 49701400 | Shares Floating 47931051 |
Shares Outstanding 49701400 | Shares Floating 47931051 | ||
Percent Insiders 3.23 | Percent Institutions 100.54 |
Upturn AI SWOT
AtriCure Inc
Company Overview
History and Background
AtriCure, Inc. was founded in 2000. It is a medical device company focused on developing, manufacturing, and selling innovative ablation solutions designed to create precise lesions, addressing unmet clinical needs for surgical treatment of atrial fibrillation (Afib) and related conditions.
Core Business Areas
- Surgical Ablation: Develops and markets surgical ablation systems used to treat Afib and other cardiovascular conditions.
- Left Atrial Appendage Management (LAAM): Offers devices for the occlusion or exclusion of the left atrial appendage to reduce the risk of stroke in patients with Afib.
- CryoICE Cryoablation: Cryoablation focuses on precise lesion creation for pain management, nerve blocks and tumor ablation in patients with lung cancer.
Leadership and Structure
Michael Carrel serves as the President and Chief Executive Officer. The company has a typical corporate structure with departments for R&D, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- AtriClip LAA Exclusion System: A device used to surgically exclude the left atrial appendage. Market share estimates vary, but AtriCure is a leading player in the LAAM market. Competitors include Boston Scientific(BSX) and Abbott (ABT).
- CryoICE Cryoablation: For Lung Cancer patients, the pain block and tumor ablation market with CryoICE is growing and is expected to keep growing. Competitors include Galil Medical (private).
- Isolator Synergy Ablation System: A bipolar radiofrequency ablation system used during open-heart surgery to create lesions in the heart tissue to treat Afib. Competitors include Medtronic (MDT) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The market for Afib treatment and cardiac surgery is growing due to an aging population and increasing prevalence of Afib. The ablation technology market is competitive and subject to technological advancements.
Positioning
AtriCure is positioned as a leader in surgical ablation and LAAM, with a focus on innovation and clinical outcomes. They have strong relationships with cardiac surgeons.
Total Addressable Market (TAM)
The global cardiac ablation market is estimated to reach $4 billion by 2028. AtriCure is well-positioned to capture a significant portion of this market through its innovative technologies and established presence.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong relationships with cardiac surgeons
- Leadership in surgical ablation and LAAM
- Extensive clinical data supporting product efficacy
- Established distribution network
Weaknesses
- Reliance on hospital capital spending
- Competition from larger medical device companies
- Potential reimbursement challenges
- Complexity of surgical procedures requiring specialized training
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary technologies or companies
- Increasing awareness of Afib and LAAM
- Improving surgical techniques and training
Threats
- Intense competition from established medical device companies
- Technological obsolescence
- Changes in healthcare regulations and reimbursement policies
- Product liability claims
- Economic downturn affecting hospital budgets
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- ABT
- BSX
Competitive Landscape
AtriCure benefits from specialized technology and strong surgeon relationships. However, Medtronic, J&J, Abbott and Boston Scientific have greater financial resources and broader product portfolios.
Major Acquisitions
SentreHEART
- Year: 2021
- Acquisition Price (USD millions): 300
- Strategic Rationale: SentreHEART expands AtriCure's LAAM portfolio by adding a percutaneous LAA closure device, complementing its surgical offerings.
Growth Trajectory and Initiatives
Historical Growth: AtriCure has experienced consistent revenue growth driven by increased adoption of its ablation and LAAM technologies.
Future Projections: Analyst estimates vary, but generally project continued revenue growth for AtriCure, driven by market expansion and new product introductions.
Recent Initiatives: AtriCure has been focused on expanding its sales force, investing in R&D, and pursuing strategic acquisitions to drive growth.
Summary
AtriCure is a leading medical device company in the surgical ablation market, particularly in atrial fibrillation treatment. Its focus on innovation and strong relationships with surgeons are key strengths. Competition from larger companies and reimbursement pressures pose challenges. Continued growth depends on successful product development and market expansion, making it a reasonably strong company to invest in.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q), Analyst Reports, Industry Publications, Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source. Financial data needs to be confirmed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AtriCure Inc
Exchange NASDAQ | Headquaters Mason, OH, United States | ||
IPO Launch date 2005-08-05 | CEO, President & Director Mr. Michael H. Carrel | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1300 | Website https://www.atricure.com |
Full time employees 1300 | Website https://www.atricure.com | ||
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.